Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking

Read all about it! In the March 2023 edition of EHJ CV Pharmacotherapy Journal - Subgroup analysis of REDUCE-IT, looking at how icosapent ethyl mitigates cardiovascular risk in smokers, ex-smokers and never smokers. My personal opinion is, wouldn’t it increase the cost for smokers, on top of their tobacco buying habits? Not sure of the message we will paint for them, like, “Hey Mr A, because you are smoking still, I’d like to give you some of these omega 3 fatty acid to reduce risk of recurrent heart attack. By the way, best to stop smoking though.” 

❓What do you think? How do we apply clinical trial findings sensibly in the real world?

👉🏻(Caveat: Subgroup Analyses should not be used to make clinical decisions, just thought to discuss these findings)

#omega3fattyacids #reducedcardiovascularrisk #cardiology #smoking #heartdisease

Michael Miller, Deepak L Bhatt, Ph Gabriel Steg, Eliot A Brinton, Terry A Jacobson, Lixia Jiao, Jean-Claude Tardif, Christie M Ballantyne, Matthew Budoff, R Preston Mason, On behalf of the REDUCE-IT Investigators, Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 2, March 2023, Pages 129–137, https://doi.org/10.1093/ehjcvp/pvac045